Accordingly, the potential impact of aromatase expression and genetic variants in CYP19A1 on levels of circulating estrogen, breast cancer risk and prognosis, and response to endocrine therapy has been extensively studied [7, 30, 51, 52]. The gene discussed is CYP19A1; the disease is breast cancer.